News
COVAXIN phase 2 study results & Phase-1 follow Up data
COVAXIN™ (BBV152) showed long-term antibody and T-cell memory responses (3-months after vaccination) in phase 1 volunteers, and tolerable safety outcomes with enhanced humoral & cell-mediated immune responses in the Phase 2 study.
Bangalore Bioinnovation Centre receives “Innovation Leadership Award”
Dr Jitendra Kumar, Managing Director of BBC said “It is an honour for team BBC to receive this award. It is great that the jury has looked into the institutions that have made the difference to the lives of others”
Ocugen and Bharat Biotech to co-develop COVAXIN™, a whole-virion inactivated COVID-19 vaccine, for the US market
Companies will co-develop inactivated vaccine candidate, COVAXIN™, to prevent COVID-19 infection in the US. Builds upon the promising safety and immunogenicity data in the Phase 1 and Phase 2 trials. Vaccine candidate is an inactivated (“traditional”) type vaccine with potentially broad appeal
India’s biggest bio entrepreneurship platform, NBEC 2020 crowns 14 winners after an intense four-month-long competition
The winners in the student-team innovation category were Tanish T. Sridhar who won the Persistent Systems sponsored cash prize of 5 lakhs INR, Chandan Kumar Jha who won the BIRAC cash prize of 3 lakhs INR, and Abduljabbar Khan who won 2 lakhs INR in a pooled prize by K&S partners, Bioneeds and Ideaspring Capital.
Exhibit in the 'India Pavilion' at BIO 2026
